Biofrontera AG BFRA
Apr 24, 2025, 3:47 PM EDT
52-week range unavailable
- Market cap
- 75.72M
- Revenue (ttm)
- 27.99M
- Profit margin
- -55.98%
- Shares out
- 28.36M
- Forward P/E
- -3.47
- Volume
- 4.95K
- Open
- 3.10
- Previous close
- 2.67
- Day's range
- 2.60 – 3.10
- Beta
- 1.55
- Analysts
- Buy
- Price target
- 8.50 (+218.4%)
- Earnings date
- Apr 11, 2022
Key statistics
- Enterprise value
- 66.26M
- PEG ratio
- 0.00
- Price / sales
- 2.71
- Price / book
- 3.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 14.10%
- Free cash flow
- 0
- Total cash
- 33.70M
- Total debt
- 24.24M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 2.89
- 200-day average
- 4.65
Analyst view
Consensus: buy
- Target (low)
- 8.00
- Target (mean)
- 8.50
- Target (high)
- 9.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 11, 2022
Expected Apr 11, 2022. Consensus EPS estimate -0.21.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 11, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 17, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Aug 19, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| May 11, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Apr 12, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
| Nov 11, 2020 | Sep 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 20, 2020 | Benchmark | main | — | Buy |
| Nov 20, 2019 | Benchmark | main | — | Buy |
| Mar 9, 2018 | Benchmark | init | — | Speculative Buy |
About Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Germany
- Website
- biofrontera.com
News
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update 
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026 
Why Is Biofrontera (BFRI) Stock Down Today? 
BFRI Stock Earnings: Biofrontera Misses EPS, Revenue Estimates 
Biofrontera AG (BFAGY) Management on Q1 2022 Results - Earnings Call Transcript 
Why Biofrontera Stock Is Surging Today 
Biofrontera Inc. (BFRI) CEO Erica Monaco on Q4 2021 Results - Earnings Call Transcript 
5 Short Squeeze Candidates To Watch: Vinco Ventures, TSR, Biofrontera And More 
Why Are Biofrontera Shares Rising Today? 
Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on BFRA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 0.05% | 14,900 | 44.25K | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Trust For Professional Managers-PMC Diversified Equity Fund | 0.01% | 2,646 | 7.86K | Dec 30, 2021 |